Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2253)
All Articles published online
|
Oct 21, 2007 (publication date) through Apr 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Jeong S, Aikata H, Katamura Y, Azakami T, Kawaoka T, Saneto H, Uka K, Mori N, Takaki S, Kodama H, Waki K, Imamura M, Shirakawa H, Kawakami Y, Takahashi S, Chayama K. Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma. World J Gastroenterol 2007; 13(39): 5188-5195 [PMID: 17876889 DOI: 10.3748/wjg.v13.i39.5188] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v13/i39/5188.htm |
| Number | Citing Articles |
| 1 |
Koji Waki, Hiroshi Aikata, Yoshio Katamura, Tomokazu Kawaoka, Shintaro Takaki, Akira Hiramatsu, Shoichi Takahashi, Naoyuki Toyota, Katsuhide Ito, Kazuaki Chayama. Percutaneous radiofrequency ablation as first‐line treatment for small hepatocellular carcinoma: Results and prognostic factors on long‐term follow up. Journal of Gastroenterology and Hepatology 2010; 25(3): 597 doi: 10.1111/j.1440-1746.2009.06125.x
|
| 2 |
Mark W. Russo. Erratum to: The Role of Interferon Therapy in Patients With Hepatocellular Carcinoma. Current Hepatitis Reports 2009; 8(S1): 35 doi: 10.1007/s11901-011-0088-0
|
| 3 |
Yoshisato Tanimoto, Hirotaka Tashiro, Hiroshi Aikata, Hironobu Amano, Akihiko Oshita, Tsuyoshi Kobayashi, Shintaro Kuroda, Hirofumi Tazawa, Shoichi Takahashi, Toshiyuki Itamoto, Kazuaki Chayama, Hideki Ohdan. Impact of Pegylated Interferon Therapy on Outcomes of Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma After Curative Hepatic Resection. Annals of Surgical Oncology 2012; 19(2): 418 doi: 10.1245/s10434-011-1866-1
|
| 4 |
Y. Miyake, A. Takaki, Y. Iwasaki, K. Yamamoto. Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. Journal of Viral Hepatitis 2010; 17(4): 287 doi: 10.1111/j.1365-2893.2009.01181.x
|
| 5 |
T. Kawaoka, H. Aikata, S. Takaki, A. Hiramatsu, K. Waki, N. Hiraga, D. Miki, M. Tsuge, M. Imamura, Y. Kawakami, S. Takahashi, H. Ochi, H. Tashiro, H. Ohdan, K. Chayama. IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma. Journal of Viral Hepatitis 2011; 18(10): e550 doi: 10.1111/j.1365-2893.2011.01468.x
|
| 6 |
Wei Teng, Wen-Juei Jeng, Hwai-I Yang, Wei-Ting Chen, Yi-Chung Hsieh, Chien-Hao Huang, Chen-Chun Lin, Chun-Yen Lin, Shi-Ming Lin, I-Shyan Sheen. Interferon Is Superior to Direct Acting Antiviral Therapy in Tertiary Prevention of Early Recurrence of Hepatocellular Carcinoma. Cancers 2019; 12(1): 23 doi: 10.3390/cancers12010023
|
| 7 |
Shoji Kubo. Prevention of cancer recurrence after treatment for hepatitis C virus-related hepatocellular carcinoma by interferon therapy. Clinical Journal of Gastroenterology 2009; 2(2): 65 doi: 10.1007/s12328-009-0072-1
|
| 8 |
Soji Shimomura, Shuhei Nishiguchi. Anticarcinogenic impact of interferon therapy on the progression of hepatocellular carcinoma in patients with chronic viral infection. Hepatology Research 2012; 42(1): 22 doi: 10.1111/j.1872-034X.2011.00889.x
|
| 9 |
Hong-Bo Huan, Li-Li Wu, Wan-Yee Lau, Xu-Dong Wen, Liang Zhang, Da-Peng Yang, Xi-Shu Wang, Ping Bie, Feng Xia. Surrogate endpoint for overall survival in assessment of adjuvant therapies after curative treatment for hepatocellular carcinoma: a re-analysis of meta-analyses of individual patients’ data. Oncotarget 2017; 8(52): 90291 doi: 10.18632/oncotarget.18853
|
| 10 |
T.‐S. Huang, Y.‐C. Shyu, H.‐Y. Chen, S.‐S. Yuan, J.‐N. Shih, P.‐J. Chen. A systematic review and meta‐analysis of adjuvant interferon therapy after curative treatment for patients with viral hepatitis‐related hepatocellular carcinoma. Journal of Viral Hepatitis 2013; 20(10): 729 doi: 10.1111/jvh.12096
|
| 11 |
Chia-Chi Wang, Jia-Horng Kao. How have the recent advances in antiviral therapy impacted the management of virus-related hepatocellular carcinoma?. Expert Opinion on Pharmacotherapy 2016; 17(7): 911 doi: 10.1517/14656566.2016.1149165
|
| 12 |
A. V. Borsukov, O. A. Gorbatenko, D. Yu. Venidiktova, A. O. Tagil, A. A. Kovalev. Multiparametric Ultrasound in the Diagnosis of Hepatocellular Carcinoma in Patients without Cirrhosis (Clinical Case). Journal of oncology: diagnostic radiology and radiotherapy 2020; 3(1): 86 doi: 10.37174/2587-7593-2020-3-1-86-93
|
| 13 |
Yuko Nagaoki, Hiroshi Aikata, Tomoki Kobayashi, Takayuki Fukuhara, Keiichi Masaki, Mio Tanaka, Noriaki Naeshiro, Takashi Nakahara, Yohji Honda, Daisuke Miyaki, Tomokazu Kawaoka, Shintaro Takaki, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Hideyuki Hyogo, Yoshiiku Kawakami, Shoichi Takahashi, Hidenori Ochi, Kazuaki Chayama. Risk factors for the exacerbation of esophageal varices or portosystemic encephalopathy after sustained virological response with IFN therapy for HCV-related compensated cirrhosis. Journal of Gastroenterology 2013; 48(7): 847 doi: 10.1007/s00535-012-0679-8
|
| 14 |
Hiroaki Hagihara, Kazuhiro Nouso, Yoshiyuki Kobayashi, Yoshiaki Iwasaki, Shinichiro Nakamura, Kenji Kuwaki, Junichi Toshimori, Hirokazu Miyatake, Hideki Ohnishi, Hidenori Shiraha, Kazuhide Yamamoto. Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. International Journal of Clinical Oncology 2011; 16(3): 210 doi: 10.1007/s10147-010-0150-x
|
| 15 |
Masatoshi Kudo. Prevention of Recurrence of Liver Cancer. Nihon Naika Gakkai Zasshi 2008; 97(7): 1681 doi: 10.2169/naika.97.1681
|
| 16 |
Hengjun Gao, Minshan Chen. Radiofrequency Ablation for Small Hepatocellular Carcinoma. 2016; : 85 doi: 10.1007/978-94-017-7258-7_10
|
| 17 |
WEI ZHANG, TIAN-QIANG SONG, TI ZHANG, QIANG WU, DA-LU KONG, QIANG LI, HUI-CHUAN SUN. Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from hepatocellular carcinoma following curative treatment: A meta-analysis with comparison of different types of hepatitis. Molecular and Clinical Oncology 2014; 2(6): 1125 doi: 10.3892/mco.2014.386
|
| 18 |
Ying-Chun Shen, Chiun Hsu, Li-Tzong Chen, Chia-Chi Cheng, Fu-Chang Hu, Ann-Lii Cheng. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approach. Journal of Hepatology 2010; 52(6): 889 doi: 10.1016/j.jhep.2009.12.041
|
| 19 |
Yan Du, Tong Su, Yibo Ding, Guangwen Cao. Effects of Antiviral Therapy on the Recurrence of Hepatocellular Carcinoma After Curative Resection or Liver Transplantation. Hepatitis Monthly 2012; 12(10) doi: 10.5812/hepatmon.6031
|
| 20 |
Gabriella Lengyel, János Fehér†. Combined interferon, ribavirin treatment and the occurrence of hepatocellular carcinoma. Orvosi Hetilap 2010; 151(29): 1177 doi: 10.1556/oh.2010.28925
|
| 21 |
Mark W. Russo. The Role of Interferon Therapy in Patients with Hepatocellular Carcinoma. Current Hepatitis Reports 2012; 11(4): 279 doi: 10.1007/s11901-010-0075-x
|